HomeInvesting NewsA Key Trial of Abivertinib in NSCLC With Sorrento Yields Promising Outcomes

A Key Trial of Abivertinib in NSCLC With Sorrento Yields Promising Outcomes

Published on


An overall response rate of 56.5% was seen in a pivotal study of Sorrento Therapeutics’ (NASDAQ:SRNE) investigational drug abivertinib for non-small cell lung cancer.

Additionally, 11 patients achieved complete responses (“CR”), for a CR rate of 5.3% and a median overall survival of 28.2 months, according to the findings.

The trial participants received extensive pretreatment.

Third-generation EGFR inhibitor abivertinib is based on pyrrolopyrimidines and differs structurally from osimertinib. When compared to EGFR that is wild-type, abivertinib specifically suppresses EGFR-activating and resistant mutations with almost 300-fold more potency. A favorable interim outcome that has been evaluated by researchers was previously reported with interim data in the peer-reviewed journal Clinical Cancer Research.

Abivertinib demonstrated significant treatment benefits in 209 response evaluable, heavily treated NSCLC patients with an ORR of 56.5% in these IRC-assessed preliminary topline results with more matured long-term follow-up data (previously 16.8 months, now 38.8 months). In addition, a significant CR rate was observed with Abivertinib (5.3%) in comparison to that of osimertinib (Tagrisso) (0.5%).

This data, which includes an ORR of 56.5%, a CR rate of 5.3%, and a median OS of 28.2 months (compared to Tagrisso’s median OS of 26.8 months)**, suggests that it may be more effective than the third-generation EGFR inhibitor that has been given approval (osimertinib). When used to treat NSCLC, abivertinib showed markedly effective results against the resistant mutation. Sorrento is wrapping up the study and getting ready to submit the pre-NDA documents and NDA package in light of these findings. With possible NDA files pending agreements with the regulatory agencies in various countries, Sorrento will ask for a pre-NDA meeting with the FDA and other regulatory agencies across the world.

According to the findings, Sorrento (NASDAQ:SRNE) said that it is ending the trial and getting ready for a pre-New Drug Application meeting with the US FDA.

Sorrento is a biopharmaceutical business in the clinical and commercial stages that is working to create novel medicines for COVID-19, autoimmune diseases, cancer, and pain (using non-opioid painkillers).

Featured Image:  Megapixl @Rafaelhenriquepress

See Disclaimer Please

Latest News

Recent Surge in Tesla Stock: Exactly What Caused It?

Tesla Stock (NASDAQ:TSLA) As of 11:30 a.m ET on Friday, Tesla stock was up 2.3%...

Here’s Why Carvana Stock Fell Quite So Much as 23.7% This Week

Carvana Stock (NYSE:CVNA) According to data provided by S&P Global Market Intelligence, Carvana stock fell...

Here’s Why Tellurian Stock Is Rising Again Today

Tellurian Stock (NYSEMKT:TELL) Tellurian stock was up 6.5% as of 11:06 p.m. ET today after...

Is It Time to Buy Chewy Stock?

Chewy Stock (NYSE:CHWY) Pet supplies are one of the few consumer goods that do well,...

More like this

2 Casino Stocks You Should Consider

With a recession on the horizon, investors must be more selective than ever. Analysts...

(Exxon Mobil Stock) Exxon Ceo Warns Biden Administration Against Restricting Fuel Exports

Exxon (Exxon Mobil Stock) opposes calls for oil corporations to reduce international exports and...

Apple Stock Loses $120 Billion Because of a Rare Downgrade

Apple stock just took a significant knock after it was once considered to be...

Meta Stock Tops Morningstar List of the Most Undervalued Stocks 

Morningstar compiled a list of the most undervalued stocks among those with a large...

Hd Stock up as Foundation to Contribute Up to $1 Million to Aid Communities Affected by Hurricane Ian

HD stock was trading at $280.23 as of 12:55 PM EDT. The Home Depot Foundation...

Making the Cut: Micron (Micron Stock)

Micron Technology Inc (Micron Stock) latest outlook brings expectations back to normal, although the...